Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Insight Into Glycyrrhetinic Acid: The Role Of The Hydroxyl Group On Liver Targeting.

Qin Tian, X. Wang, W. Wang, Chuang-Nian Zhang, Yayuan Liu, Zhi Yuan
Published 2010 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Two kinds of glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles (CTS/PEG-GA NPs) were prepared by an ionic gelation process in which the liver targeting ligand glycyrrhetinic acid (GA) was introduced into the nanoparticles at the C(30)-carboxyl group (CTS/PEG-GA(c) NPs) or the C(3)-hydroxyl group (CTS/PEG-GA(h) NPs). Their characteristics, especially their ability to target the liver, were compared. The results showed that both the CTS/PEG-GA(c) NPs and the CTS/PEG-GA(h) NPs are remarkably targeted to the liver. The accumulation in the liver is 51.3% and 56.5% of the injected dose for the CTS/PEG-GA(c)(4.60%) NPs (the subscript number denotes the GA content as weight percent in nanoparticles) and the CTS/PEG-GA(h)(4.57%) NPs at 3 h after injection, respectively. This is nearly 2.6-2.8 times higher than that obtained with the CTS/PEG NPs. According to our results, there is no significant difference between the CTS/PEG-GA(c) NPs and the CTS/PEG-GA(h) NPs in their ability to target the liver, when they were formed under identical conditions. This indicated that the C(3)-hydroxyl group in GA has little influence on the targeting ability.
This paper references
10.1016/S0928-0987(02)00257-9
Self-assembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system.
K. Na (2003)
Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies.
A. Gabizon (1990)
10.1016/J.BMC.2007.05.057
The synthesis of 18beta-glycyrrhetinic acid derivatives which have increased antiproliferative and apoptotic effects in leukemia cells.
Dan Liu (2007)
10.1002/ptr.2295
Antiviral effects of Glycyrrhiza species
C. Fiore (2008)
10.1016/j.actbio.2010.04.021
Glycyrrhetinic acid-modified poly(ethylene glycol)-b-poly(gamma-benzyl l-glutamate) micelles for liver targeting therapy.
W. Huang (2010)
10.1002/ptr.2362
Review of Pharmacological Effects of Glycyrrhiza sp. and its Bioactive Compounds
M. N. Asl (2008)
Preparation, characterization and uptake by primary cultured rat hepatocytes of liposomes surface-modified with glycyrrhetinic acid.
S. Mao (2007)
10.1016/j.bmc.2009.10.036
Synthesis of glycyrrhetinic acid derivatives for the treatment of metabolic diseases.
Igor Beseda (2010)
10.1111/j.1478-3231.2007.01452.x
Hepatic stellate cell‐targeted delivery of M6P‐HSA‐glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model
J. Luk (2007)
10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4
Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers
P. Calvo (1997)
10.1016/j.biomaterials.2010.02.042
Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
Q. Tian (2010)
10.1002/APP.1993.070480218
pH‐sensitivity of hydrogels based on complex forming chitosan: Polyether interpenetrating polymer network
K. Yao (1993)
10.1016/0005-2736(91)90253-5
Specific binding of glycyrrhetinic acid to the rat liver membrane.
M. Negishi (1991)
10.1016/j.ijpharm.2008.03.039
Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery.
Aihua Lin (2008)
10.1124/dmd.108.021089
Down-Regulation of a Hepatic Transporter Multidrug Resistance-Associated Protein 2 Is Involved in Alteration of Pharmacokinetics of Glycyrrhizin and Its Metabolites in a Rat Model of Chronic Liver Injury
T. Makino (2008)



This paper is referenced by
10.1016/j.ejps.2016.09.036
Synthesis, characterization and liver targeting evaluation of self‐assembled hyaluronic acid nanoparticles functionalized with glycyrrhetinic acid
Xiaodan Wang (2017)
10.1016/B978-0-323-46144-3.00017-9
Ligand-decorated polysaccharide nanocarriers for targeting therapeutics to hepatocytes
Sabyasachi Maiti (2017)
10.1016/j.nano.2018.09.012
A conveniently synthesized Pt (IV) conjugated alginate nanoparticle with ligand self-shielded property for targeting treatment of hepatic carcinoma.
X. Wang (2019)
10.1021/acs.molpharmaceut.5b00677
Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy.
Yuee Cai (2016)
10.1016/j.colsurfb.2015.08.031
Controllable targeted system based on pH-dependent thermo-responsive nanoparticles.
Chengling Yang (2015)
10.2147/IJN.S153944
Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes
Y. Sun (2018)
10.1016/j.nano.2011.11.002
Self-assembly and liver targeting of sulfated chitosan nanoparticles functionalized with glycyrrhetinic acid.
Q. Tian (2012)
10.1016/j.bioorg.2020.103804
Synthesis and anti-hepaticfibrosis of glycyrrhetinic acid derivatives with inhibiting COX-2.
Qiuping Zhang (2020)
10.2217/nnm-2018-0455
Biodistribution and biocompatibility of glycyrrhetinic acid and galactose-modified chitosan nanoparticles as a novel targeting vehicle for hepatocellular carcinoma.
M. Li (2019)
10.1016/j.ijpharm.2012.10.030
Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs.
L. Zhang (2013)
10.2174/1389450115666140309232100
Recent advances in active hepatic targeting drug delivery system.
Y. Wang (2014)
10.1016/j.ijbiomac.2012.05.005
Optimization on condition of glycyrrhetinic acid liposome by RSM and the research of its immunological activity.
X. Zhao (2012)
10.3109/10717544.2013.853850
A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects
J. Tian (2014)
10.1007/s10118-014-1432-y
Studies on antineoplastic effect by adjusting ratios of targeted-ligand and antitumor drug
H. Guo (2014)
10.3109/08982104.2011.627515
HPLC assay and pharmacokinetics and tissue distribution study of glycyrrhetinic acid liposomes modified with galactosylated lipid
Bo-hong Guo (2012)
10.1016/j.fitote.2011.10.018
Glycyrrhetinic acid protects mice from Staphylococcus aureus pneumonia.
Hong-en Li (2012)
10.1007/s10856-011-4262-2
Glycyrrhetinic acid-functionalized degradable micelles as liver-targeted drug carrier
W. Huang (2011)
10.1007/s11095-015-1714-2
Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma
J. Zhang (2015)
10.1007/s10856-011-4494-1
Design and synthesis of dual-ligand modified chitosan as a liver targeting vector
Houxiang Chen (2011)
10.1155/2013/913654
Glycyrrhetinic Acid-Poly(ethylene glycol)-glycyrrhetinic Acid Tri-Block Conjugates Based Self-Assembled Micelles for Hepatic Targeted Delivery of Poorly Water Soluble Drug
Fengbo Wu (2013)
10.3109/1061186X.2012.685475
The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid
J. Li (2012)
10.1016/j.bcp.2020.114232
Paclitaxel and betulonic acid synergistically enhance antitumor efficacy by forming co-assembled nanoparticles.
J. Wang (2020)
10.1016/j.carbpol.2018.04.052
Enhanced delivery of doxorubicin to the liver through self-assembled nanoparticles formed via conjugation of glycyrrhetinic acid to the hydroxyl group of hyaluronic acid.
Xiaodan Wang (2018)
10.3390/pharmaceutics11070325
Nanoconjugation and Encapsulation Strategies for Improving Drug Delivery and Therapeutic Efficacy of Poorly Water-Soluble Drugs
Thao Tran (2019)
10.1021/mp500394v
Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
Wen-Wen Qi (2015)
10.1186/s11671-018-2737-5
Preparation of Glycyrrhetinic Acid Liposomes Using Lyophilization Monophase Solution Method: Preformulation, Optimization, and In Vitro Evaluation
Tingting Liu (2018)
10.1016/j.nano.2015.12.381
Drug delivery system targeting advanced hepatocellular carcinoma: Current and future.
X. Zhang (2016)
10.1016/j.bmcl.2012.03.081
Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents.
L. Wang (2012)
10.1016/j.semcancer.2019.08.016
Nanomedicine As A Putative Approach For Active Targeting of Hepatocellular Carcinoma.
M. H. Elnaggar (2019)
10.1007/978-3-319-11355-5_6
Hepatic Targeting: Physiological Basis and Design Strategy
A. D’souza (2015)
10.1016/j.ijbiomac.2018.10.049
Modified hyaluronic acid based materials for biomedical applications.
Sanjay Tiwari (2019)
10.1039/C8TB01657G
Iron oxide nanoparticles for targeted imaging of liver tumors with ultralow hepatotoxicity.
J. Li (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar